Swiss Dental Med-Tech vVARDIS Prices NYSE IPO at $18 a Share
Summary
vVARDIS, a Zug-based dental med-tech company selling the Curodont brand of non-invasive cavity treatments, priced its IPO at $18.00 per share for 9,722,223 Class A ordinary shares, roughly $175M in gross proceeds before the greenshoe. Underwriters hold a 30-day option on up to 1,458,333 more shares. The stock starts trading on the NYSE under VVVV on November 13, 2026, with the offering expected to close on or about November 16. Goldman Sachs and J.P. Morgan are joint bookrunning managers, with William Blair, UBS and Deutsche Bank as bookrunners. The F-1 was declared effective November 12. This is the first tradeable reference point for the name — the $18 clearing price and the size of the book are what matter for anyone taking a position at the open.
This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.